| Literature DB >> 35346073 |
Yu Lv1, Xiaobo Huang2, Yunping Lan2, Qi Xia3, Fuli Chen4, Jiayu Wu5, Wei Li5, Hongrong Cao5, Caixia Xie6, Luting Li7, Hukui Han8, Hui Wang9, Qian Xiang10.
Abstract
BACKGROUND: The prevention of peripherally inserted central catheters (PICC)-associated BSI and central venous catheters (CVC)-associated BSI have been a topic of national importance in China. Therefore, we aimed to explore the epidemiological characteristics of central line-associated bloodstream infection (CLABSI), and to evaluate whether PICCs were associated with a protective effect for CLABSI.Entities:
Keywords: Bloodstream infection; Central venous catheter; Peripherally inserted central catheter; Propensity score matching; Restricted cubic spline regression
Mesh:
Year: 2022 PMID: 35346073 PMCID: PMC8961920 DOI: 10.1186/s12879-022-07265-x
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Cases selection algorithm for our study population. We excluded 774 patients younger than 18 years and 4495 patients who did not meet CLABSI diagnostic criteria, resulting in 4775 patients with CVC and 20,104 patients with PICC were included in the analysis
Baseline characteristics
| Variable | Pre-PSM, No. (%) | Post-PSM, No. (%) | ||||
|---|---|---|---|---|---|---|
| PICC (n = 20,104) | CVC (n = 4775) | SMD | PICC (n = 5390) | CVC (n = 2695) | SMD | |
| Age, mean (SD), y | 56.84 (14.78) | 60.69 (17.30) | 0.239 | 57.89 (16.27) | 58.57 (17.20) | 0.041 |
| Male | 10,466 (52.1) | 3038 (63.6) | 0.236 | 3050 (56.6) | 1581 (58.7) | 0.042 |
| Year | ||||||
| 2017 | 3976 (19.8) | 1018 (21.3) | 0.038 | 1243 (23.1) | 623 (23.1) | 0.001 |
| 2018 | 4788 (23.8) | 1176 (24.6) | 0.019 | 1462 (27.1) | 707 (26.2) | 0.020 |
| 2019 | 5373 (26.7) | 1218 (25.5) | 0.028 | 1345 (25.0) | 665 (24.7) | 0.006 |
| 2020 | 5967 (29.7) | 1363 (28.5) | 0.025 | 1340 (24.9) | 700 (26.0) | 0.026 |
| Community Infections | 902 (4.5) | 1123 (23.5) | 0.570 | 757 (14.0) | 414 (15.4) | 0.037 |
| Blood Transfusion | 6632 (33.0) | 3064 (64.2) | 0.657 | 3020 (56.0) | 1548 (57.4) | 0.028 |
| Urinary Catheterization | 8842 (44.0) | 3472 (72.7) | 0.609 | 3393 (62.9) | 1806 (67.0) | 0.085 |
| Hemodialysis | 174 (0.9) | 65 (1.4) | 0.047 | 56 (1.0) | 27 (1.0) | 0.004 |
| Mechanical Ventilation | 3625 (18.0) | 3222 (67.5) | 1.154 | 2453 (45.5) | 1325 (49.2) | 0.073 |
| Tracheotomy | 191 (1.0) | 570 (11.9) | 0.459 | 163 (3.0) | 115 (4.3) | 0.066 |
| Hypertension | 5005 (24.9) | 1629 (34.1) | 0.203 | 1599 (29.7) | 844 (31.3) | 0.036 |
| Diabetes mellitus | 2418 (12.0) | 958 (20.1) | 0.220 | 868 (16.1) | 478 (17.7) | 0.044 |
| COPD | 379 (1.9) | 505 (10.6) | 0.366 | 211 (3.9) | 129 (4.8) | 0.043 |
| Malignancy | 9434 (46.9) | 471 (9.9) | 0.902 | 572 (10.6) | 343 (12.7) | 0.066 |
| Liver Failure | 152 (0.8) | 274 (5.7) | 0.284 | 130 (2.4) | 81 (3.0) | 0.037 |
| Renal Failure | 609 (3.0) | 692 (14.5) | 0.414 | 355 (6.6) | 250 (9.3) | 0.095 |
| Heart Failure | 477 (2.4) | 418 (8.8) | 0.281 | 259 (4.8) | 169 (6.3) | 0.064 |
| Respiratory Failure | 392 (1.9) | 1573 (32.9) | 0.895 | 362 (6.7) | 265 (9.8) | 0.113 |
| Principal diagnosis | ||||||
| Certain infectious diseases and parasites | 601 (3.0) | 258 (5.4) | 0.121 | 291 (5.4) | 147 (5.5) | 0.002 |
| Tumor | 9595 (47.7) | 313 (6.6) | 1.045 | 485 (9.0) | 289 (10.7) | 0.058 |
| Blood and hematopoietic diseases and certain diseases involving immune mechanisms | 197 (1.0) | 15 (0.3) | 0.083 | 37 (0.7) | 15 (0.6) | 0.017 |
| Endocrine, nutritional, and metabolic diseases | 136 (0.7) | 86 (1.8) | 0.102 | 123 (2.3) | 55 (2.0) | 0.017 |
| Mental and behavioral disorders | 9 (0.0) | 16 (0.3) | 0.067 | 9 (0.2) | 8 (0.3) | 0.027 |
| Nervous system diseases | 83 (0.4) | 113 (2.4) | 0.167 | 74 (1.4) | 44 (1.6) | 0.021 |
| Eye and appendage diseases | 2 (0.0) | 0 (0.0) | 0.014 | 0 (0.0) | 0 (0.0) | / |
| Ear and mastoid diseases | 2 (0.0) | 0 (0.0) | 0.014 | 0 (0.0) | 0 (0.0) | / |
| Circulatory diseases | 1892 (9.4) | 1098 (23.0) | 0.375 | 1627 (30.2) | 738 (27.4) | 0.062 |
| Respiratory diseases | 730 (3.6) | 1054 (22.1) | 0.573 | 484 (9.0) | 251 (9.3) | 0.012 |
| Digestive diseases | 1464 (7.3) | 755 (15.8) | 0.269 | 1079 (20.0) | 526 (19.5) | 0.013 |
| Skin and subcutaneous tissue diseases | 11 (0.1) | 10 (0.2) | 0.043 | 10 (0.2) | 7 (0.3) | 0.016 |
| Musculoskeletal system and connective tissue diseases | 288 (1.4) | 42 (0.9) | 0.052 | 68 (1.3) | 33 (1.2) | 0.003 |
| Genitourinary diseases | 1524 (7.6) | 142 (3.0) | 0.207 | 279 (5.2) | 128 (4.7) | 0.020 |
| Pregnancy, childbirth, and puerperium | 99 (0.5) | 20 (0.4) | 0.011 | 43 (0.8) | 16 (0.6) | 0.025 |
| Congenital malformations, deformation, and chromosomal abnormalities | 407 (2.0) | 11 (0.2) | 0.171 | 18 (0.3) | 11 (0.4) | 0.012 |
| Abnormal symptoms, signs, clinical and laboratory results, and cannot be classified in other categories | 41 (0.2) | 28 (0.6) | 0.061 | 40 (0.7) | 18 (0.7) | 0.009 |
| Injury, poisoning and other external pathogenic factors | 723 (3.6) | 810 (17.0) | 0.451 | 717 (13.3) | 405 (15.0) | 0.049 |
| External causes of illness and death | 2300 (11.4) | 4 (0.1) | 0.503 | 6 (0.1) | 4 (0.1) | 0.010 |
CLABSI among the 4 sites of catheterization
| Catheter location | Pre-PSM, No. (%) | Post-PSM, No. (%) | ||||
|---|---|---|---|---|---|---|
| CLABSI (n = 407) | Non-CLABSI (n = 24,472) | CLABSI (n = 164) | Non-CLABSI (n = 7921) | |||
| Catheter insertion sites | < 0.001 | < 0.001 | ||||
| PICC | 152 (0.8) | 19,952 (99.2) | 71 (1.3) | 5319 (98.7) | ||
| Femoral | 74 (6.2) | 1128 (93.8) | 28 (3.8) | 707 (96.2) | ||
| Subclavian | 71 (5.2) | 1284 (94.8) | 25 (3.5) | 697 (96.5) | ||
| Internal Jugular | 53 (4.5) | 1115 (95.5) | 22 (3.3) | 640 (96.7) | ||
| Unclear | 7 (2.7) | 255 (97.3) | 5 (3.1) | 156 (96.9) | ||
| Femoral + Subclavian | 46 (6.4) | 670 (93.6) | 12 (3.2) | 366 (96.8) | ||
| Femoral + Internal Jugular | 3 (6.0) | 47 (94.0) | 1 (3.8) | 25 (96.2) | ||
| Subclavian + Internal Jugular | 1 (4.8) | 20 (95.2) | 0 (0.0) | 10 (100.0) | ||
| Femoral + Subclavian + Internal Jugular | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | ||
Fig. 2Restricted cubic spline of CLABSI risk. A OR value increased rapidly in the first 8 calendar days after CVC insertion. However, after the 8th calendar day the OR value became stable. B In the first 4 calendar days after PICC insertion, the OR value increased day by day, reached a relatively high point on the 4th calendar day, and decreased from days 5 through 8. However, after the 8th calendar day the OR value began to increase day by day again
Fig. 3Standardized mean differences before and after matching. PSM improved the balance on the investigated baseline characteristics with all SMD between groups decreasing to 0.1 or less except for the respiratory failure
Fig. 430-day CLABSI hazard before and after propensity score matching. A In the whole cohort, patients with CVC had a significantly higher 30-day CLABSI hazard compared with patients with PICC (HR = 6.76, 95% CI 5.53–8.27). B In the PSM cohort, patients with CVC also had a significantly higher 30-day CLABSI hazard compared with patients with PICC (adjHR = 3.27, 95% CI 2.38–4.49)